Compare 8x8 Inc (EGHT) vs Cassava Sciences Inc (FLNA) Price & Performance

EGHT trades at $2.13, down 0.47% on the day, with a bullish technical signal from moving averages. The company reported three consecutive earnings beats and shows improving profitability trends with 2026 projected net income of $5M. Recent news highlights cost-saving client wins and AI product growth, while analyst consensus targets $19.77 with mixed ratings.

The stock presents a high-risk opportunity with significant upside potential if the company executes on its turnaround. Key risks include high debt levels and negative retained earnings, but improving cash flow and margin expansion could drive revaluation. Current valuation metrics show a high P/E ratio but attractive P/S multiple.

FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.

The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.